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Mammals encode proteins that inhibit viral replica-
tion at the cellular level. In turn, certain viruses have
evolved genes that can functionally counteract these
intrinsic restrictions. Human CD317 (BST-2/HM1.24/
tetherin) is a restriction factor that blocks release of
human immunodeficiency virus type 1 (HIV-1) from
the cell surface and can be overcome by HIV-1 Vpu.
Here, we show that mouse and rat CD317 potently
inhibit HIV-1 release but are resistant to Vpu. Inter-
species chimeras reveal that the rodent-specific
resistance and human-specific sensitivity to Vpu
antagonism involveall threemajor structural domains
of CD317. To promote virus release, Vpu depletes
cellular pools of human CD317, but not of the rodent
orthologs, by accelerating its degradation via the
20S proteasome. Thus, HIV-1 Vpu suppresses the
expression of the CD317 antiviral factor in human
cells, and the species-specific resistance to this
suppression may guide the development of small
animal models of HIV infection.
INTRODUCTION
Besides classical innate and acquired immune responses,
mammals have evolved a set of dominant genes that are capable
of suppressing or preventing virus replication at the host cell
level. Among these major cellular defenses against retroviral
infection are the Friend virus susceptibility-1 (Fv1) gene product
and members of the tripartite interaction motif (TRIM) family,
both of which target incoming retroviral particles (Goff, 2004;
Sebastian and Luban, 2007; Towers, 2007), with some TRIM
proteins apparently also interfering with transcription (Wolf and
Goff, 2007) or late steps in the retroviral replication cycle (Sakuma
et al., 2007; Uchil et al., 2008). A second major cellular antiviral
activity has been identified for members of the apolipoprotein
editing complex (APOBEC) class of cytidine deaminases that
hypermutate and/or destabilize viral genomes, including HIV,
Moloney murine leukemia virus, hepatitis B virus, human papil-Cell Hloma viruses (Vartanian et al., 2008), and endogenous retroele-
ments (Chiu and Greene, 2008). These restriction factors, which
typically are constitutively expressed but can frequently be upre-
gulated by host cells in response to virus infection, appear to
impose particularly effective barriers in the context of cross-
species transmission of viruses (Chiu andGreene, 2008; Towers,
2007). Accordingly, they have been classified as belonging to the
‘‘intrinsic’’ immunity, representing an innate cellular network for
the front-line defense in an immunologically naive host (Bieniasz,
2004).
Recently, human CD317 was identified as an additional IFNa-
inducible restriction factor, the expression of which prevents
the final step in the release of fully matured HIV particles from
infected cells through surface-protein-based tethers (Neil et al.,
2008; Van Damme et al., 2008). Accordingly, the molecule has
also been referred to as ‘‘tetherin’’ (Neil et al., 2008). In addition,
human CD317-expressing cells apparently display an enhanced
endocytosis of mature virions from the surface into CD63-posi-
tive compartments. The physiological function of CD317,
however, is currently unknown. CD317 is an integral membrane
protein expressed constitutively on terminally differentiated B
cells (Goto et al., 1994), bone marrow stromal cells (Ishikawa
et al., 1995), and plasmacytoid dendritic cells (Blasius et al.,
2006). It has been noted that CD317 can be upregulated in
most cell types following IFN stimulation (Blasius et al., 2006).
HIV-1 encodes a unique set of accessory gene products to
optimize its replication in the human host, and this is achieved
in part by counteracting host restriction factors (Malim andEmer-
man, 2008;Simonet al., 1998;Varthakavi et al., 2003). The viral Vif
protein, for example, depletes cellular APOBEC3G pools and
thus prevents APOBEC3G encapsidation into HIV particles,
ensuring high infectivity of viral progeny (Chiu and Greene,
2008). TheHIV-1accessoryproteinVpuandseveralHIVenvelope
glycoproteins share theability toovercomeadominant restriction
of virion release in certain human cells, including T cells and
macrophages (Bour et al., 1996; Go¨ttlinger et al., 1993; Iida
et al., 1999; Klimkait et al., 1990; Noble et al., 2006; Ritter et al.,
1996; Schubert et al., 1999, 1995; Strebel, 2007; Varthakavi
et al., 2003). The observation that Vpu can counteract CD317-
mediated release inhibition (Neil et al., 2008; Van Damme et al.,
2008) suggested that CD317 may constitute this long-sought
restriction factor. The mechanism by which Vpu counteractsost & Microbe 5, 285–297, March 19, 2009 ª2009 Elsevier Inc. 285
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activity of the intrinsic immunity factor (Neil et al., 2007) are there-
fore particularly important topics.
In the current study, we report that the release-specific antire-
troviral activity of CD317 is conserved between the human and
rodent orthologs in spite of extensive amino acid sequence
divergence. Analysis of the activity of the virus-encoded antago-
nist Vpu unmasks a striking difference for the interaction of the
human pathogen with the three CD317 orthologs. Mechanisti-
cally, cellular levels of human but not of rodent CD317 are
reduced in the presence of Vpu, resulting in a rescue of HIV-1
release. Vpu achieves this depletion by targeting human CD317
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Figure 1. Human, Mouse, and Rat CD317
Restrict HIV-1 Particle Release
(A) Sequence alignment of CD317 of human,
mouse, and rat origin (ClustalW2 method and
BOXSHADE). Identical amino acids are shaded
in black, conserved or similar residues are in
gray, and unrelated amino acids in white (identity
scores determined by Vector NTI). The predicted,
unusual topology (Kupzig et al., 2003) includes an
amino-terminal cytoplasmic tail; sequences
boxed in red indicate the predicted position of
the transmembrane domain. In the extracellular
coiled-coil domain, the two putative N-glycosyla-
tion sites are boxed in green, and the serine resi-
dues that are predicted as the site of cleavage
prior to C-terminal addition of a GPI anchor is
highlighted in blue.
(B–E) Impact of HA-tagged CD317 from all three
species in HIV-1Dvpu-expressing 293T cells on
the yield of virion-associated p24CA antigen (B)
and infectious HIV-1 virions in culture superna-
tants (E) and levels of cell-associated p24CA (C).
Effect of CD317 on HIV-1 release was expressed
as the percentage of total p24CA (in cells and
supernatant) that was secreted as virion-associ-
ated p24CA in (D). Values are arithmetic means ±
SD of triplicates from one representative experi-
ment out of four.
(F) Corresponding western blot analysis of 293T
cell lysates for HA-CD317 and MAPK expression.
for degradation via the 20S proteasome.
Our results highlight CD317-mediated
antiretroviral defense and viral evasion of
this intrinsic immune factor as remarkable
examples of theconstantly evolvingbattle
of retroviruses with natural and potential
hosts.
RESULTS
CD317 from Human, Mouse,
and Rat Inhibits HIV-1 Release
The amino acid sequences of mouse (m)
and rat (r) CD317 display extensive diver-
gence from their human (h) ortholog,
sharing only 41% and 36% sequence
identity, respectively (Figure 1A). The
rodent orthologs are 71% identical to
each other. We first tested whether anti-HIV-1 activity is a
conserved function of CD317 in spite of this sequence diversity.
To assess their effect on HIV-1 production, N-terminally HA-
epitope-tagged CD317 proteins were coexpressed with Vpu-
defective HIV-1 (HIV-1Dvpu) in human 293T cells, which normally
harbor low or no endogenous hCD317 expression (Neil et al.,
2008; Van Damme et al., 2008). The three CD317 proteins
displayed species-specific migration patterns on SDS-PAGE
(Figure 1F), reflecting differential N-glycosylation (Figure S1)
(Kupzig et al., 2003). The yield of Vpu-defective HIV-1 virions
was drastically reduced relative to the vector control following
transient expression of all three CD317 orthologs, as assessed
286 Cell Host & Microbe 5, 285–297, March 19, 2009 ª2009 Elsevier Inc.
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ure1B) and infectiousHIV-1 (39- to650-fold reduction) (Figure1E)
that were released into culture supernatants. In contrast, cell-
associated levels of p24CA were nearly identical in the presence
or absence of CD317 (Figure 1C). Based on the values shown in
Figures 1B and 1C, the effect of CD317 on HIV-1 release was ex-
pressed as the percentage of total p24CA (in cells and superna-
tant) that was secreted as virion-associated p24CA (Figure 1D).
This approach has been used previously by others (Bour et al.,
1999; Van Damme et al., 2008; Varthakavi et al., 2008). Thus, as
observed for hCD317, CD317 from mouse and rat potently
restricts the production of Vpu-defective HIV-1.
Rodent and Human CD317 Restrict the Release
of Mature HIV-1 Virions
To address whether CD317 proteins have an impact on the
synthesis, processing, or degradation of HIV-1 Gag, [35S]methio-
nine pulse-chase radiolabeling studies were performed in 293T
cells cotransfected with an expression plasmid encoding
codon-optimized HIV-1 GagPol and expression plasmids for the
different HA-CD317 proteins or HA alone (vector). A concurrent
virological assessment under these experimental conditions
showed a strong inhibition of release of Env-deficient HIV-1
virus-like particles (Figure S2), similar to that observed with
Vpu-defectiveHIV-1 (Figures 1B–1D). After 30minpulse-labeling,
amounts of the unprocessed Pr55Gag precursor and processed
p24CAwere comparable or slightly reducedbyCD317coexpres-
sion, and, expectedly, no released particles could be detected
(Figure 2A, left panels). After a 4 hr chase period, the majority of
Pr55Gag was processed to p24CA under all conditions (Fig-
ure 2A, right panels). Most significantly, the release of radiola-
beled virions was markedly reduced upon coexpression of
CD317 from all three species, consistent with the steady-state
analyses in Figure 1B. Thus, neither human nor rodent CD317
have a pronounced effect on HIV-1 Gag synthesis and process-
ing, but impair the release of newly assembled, mature virions.
We next assessed whether expression of rodent CD317
induces an accumulation of HIV-1 Gag and virions at the cell
surface and in vesicular compartments as reported for the human
ortholog, applying a morphological quantification scheme intro-
duced by Neil and colleagues (Neil et al., 2008). The anti-p24CA
staining of HIV-1Dvpu-transfected 293T cells showed a diffuse
punctate distribution in the cytoplasm (Figure 2B, vector), while
expression of all three HA-tagged CD317 proteins induced
a marked redistribution of the major structural Gag protein,
highlighted by its enrichment in large aggregates at the plasma
membrane and/or intracellularly (Figures 2B and S3 for quantifi-
cation). In these HIV-1-expressing cells, HA-CD317 proteins
predominantly localized to intracellular compartments/large
vesicular structures frequently found in a ring-like pattern under-
neath the plasma membrane or around the nucleus; this is
consistent with the previously described localization of intracel-
lular CD317 (Kupzig et al., 2003). It is of note that provirally
encoded HIV-1 Gag and HA-CD317 typically did not colocalize,
which is in contrast to results reported for a codon-optimized
Gag.GFP fusion protein (Neil et al., 2008).
Immunoelectron microscopy of cells cotransfected with plas-
mids expressing HIV-1NL4-3 wild-type (HIV-1WT) and HA-CD317
revealed clustered virions at or underneath the plasmaCell Hmembrane, which were strongly labeled with anti-p24CA
(Figure 2C [15 nm gold, arrowheads]). HA-hCD317 was
frequently found in vesicular structures adjacent to viral particles
(Figure 2C [10 nm gold, arrow]) with weaker staining of the
plasma membrane. HIV-1 budding sites and virus particles ex-
hibited no apparent enrichment in anti-HA labeling compared
to the surrounding plasma membrane (Figure 2C and data not
shown).
Thin-section electron microscopic analysis of epoxy resin
sections from 293T cells transfected with HIV-1Dvpu provirus
and a control vector showed occasional immature and mature
virions associated with the plasma membrane (Figure 2D,
vector). In contrast, expression of CD317 from humans or
rodents resulted in accumulation of mature virions attached to
the surface or to each other in a fair number of cells (Figure 2D).
Mature virions were also observed in what appear to be intracel-
lular compartments in CD317-expressing 293T cells (Figure 2D
[arrows]); however, the identity of these compartments and
their possible communication with the cell surface is currently
unclear.
Together, these results demonstrate that human and rodent
CD317 do not markedly interfere with HIV-1 Gag synthesis and
processing, but share the ability to inhibit release of infectious
HIV-1 by leading to the tethering of mature particles to the
surface of virus-producing cells and by inducing the accumula-
tion of virions in plasma membrane-adjacent compartments.
The Rodent Orthologs of CD317 Are Resistant
to Counteraction by HIV-1 Vpu
Recent studies demonstrated that the inhibition of virion release
by CD317 from humans can be antagonized by Vpu (Neil et al.,
2008; Van Damme et al., 2008). Here, we explored the suscepti-
bility of the HIV-1 restriction imposed bymouse and rat CD317 to
Vpu antagonism. First, virion production was quantified from
293T cells cotransfected with decreasing amounts of expression
plasmids encoding authentic, untagged CD317 from all three
species and a proviral plasmid encoding either HIV-1 WT or the
isogenic Vpu-defective counterpart, HIV-1Dvpu. In the absence
of ectopic CD317 expression, levels of virions in the supernatant
were in a similar range for HIV-1 WT and HIV-1Dvpu (Figure 3A,
vector), confirming recent reports (Neil et al., 2008; Van Damme
et al., 2008). The highest levels of ectopically expressed hCD317
potently reduced HIV-1 release and induced virion tethering irre-
spective of the Vpu status (Figures 3A and 3B; see also EM
images for HIV-1 WT in Figure S4). Titration of the human restric-
tion factor, however, revealed that at lower levels of hCD317
expression, particle release was rescued for HIV-1 WT, but not
for Vpu-defective HIV-1 (Figures 3A and 3B, left panels). In stark
contrast, the ability of m- and rCD317 to inhibit particle release
was virtually indistinguishable for HIV-1 WT and HIV-1Dvpu
(Figures 3A and 3B, middle and right panel). Collectively, provir-
ally encoded Vpu antagonizes the anti-HIV-1 activity of hCD317,
but this counteraction can be overcome at high levels of the
restriction factor. The impact of the rodent orthologs on HIV-1
release, on the other hand, is Vpu-resistant.
To corroborate and extend these findings, we used an exper-
imental setup that allowed us to assess the effect of different
expression levels of the viral antagonist Vpu onCD317-mediated
inhibition of HIV-1 release. 293T cells were cotransfected withost & Microbe 5, 285–297, March 19, 2009 ª2009 Elsevier Inc. 287
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Figure 2. Impact of Human and Rodent CD317 on HIV-1 Gag by Pulse-Chase and Imaging Analyses
(A) Pulse-chase radiolabeling. 293T cells transiently transfected with psyngagpol and expression plasmids for HA-CD317 or a vector control were pulse-labeled
and then incubated with chase medium for 4 hr. After immunoprecipitation of cell lysates or supernatant with anti-p24CA antiserum, the proteins were separated
by SDS-PAGE, and the gels were subjected to autoradiography. Shown are the results of one representative experiment out of three.
(B) Merged confocal micrographs for the localization of HIV-1 Gag (green, anti-p24CA) and HA-CD317 (red, anti-HA) in HIV-1Dvpu-cotransfected 293T cells.
Arrows indicates a typical intracellular (vesicular) Gag stain; arrow heads depict a typical plasma membrane Gag stain. Scale bar: 10 mm. Shown are the results
of one representative experiment out of two.
(C) Electron microscopic localization of p24CA and HA-hCD317 in immunolabeled cryosections of 293T cells cotransfected with pHIV-1 WT (1.2 mg) and
pcDNA3.1-HA-hCD317 (1.2 mg). Arrow heads indicate p24CA-labeled virions (15 nm gold); the arrow indicates vesicles labeled for HA-hCD317 (10 nm gold).
PM: plasma membrane, scale bar: 200 nm.
(D) Electron microscopic images from epoxy resin-embedded sections of 293T cells cotransfected with pHIV-1Dvpu (1.2 mg) and expression plasmids for the
indicated HA-CD317 orthologs (1.2 mg) or a control vector. Arrows indicate intracellular accumulations of HIV-1 particles. Scale bars: 200 nm.proviral DNA encoding HIV-1Dvpu and constant, intermediate
amounts of expression plasmids encoding HA-CD317. Under
these experimental conditions, HA-hCD317 caused a pro-
nounced restriction of HIV-1Dvpu virion release. Importantly,
the release of Vpu-defective HIV-1 could be rescued by trans-
complemented Vpu in a concentration-dependent manner
(Figure 3C). Notably, immunodetection of Vpu turned out to be
rather nonlinear (Figure 3D), hampering quantitative assessment
of the dose-effect relationship. Inhibition of virus release by
CD317 from mouse and rat, however, could not be overcome
by expression of Vpu (Figure 3C). This was true even at levels288 Cell Host & Microbe 5, 285–297, March 19, 2009 ª2009 Elsevieof Vpu expression that apparently exceeded those expressed
by HIV-1 WT (Figure 3D).
The Sensitivity of CD317 to Vpu Antagonism Has
a Complex Genetic Basis Involving All Three Major
Structural Domains of the Restriction Factor
CD317 is an integral membrane protein with a highly unusual pre-
dicted topology: the amino-terminal cytoplasmic tail (CT) is fol-
lowed by a single transmembrane domain (TM), an extracellular
coiled-coil domain (ED), and a putative glycosyl phosphatidylino-
sitol membrane anchor at the C terminus (Kupzig et al., 2003;r Inc.
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Species-Specific CD317 Subversion by HIV-1Neil et al., 2008) (Figure 1A; insets in Figure 4). To map domains
of the restriction factor that determine resistance or susceptibility
to Vpu antagonism, we constructed a set of expression plas-
mids encoding HA-tagged CD317 chimeras with reciprocal
exchanges of either the CT, TM, or ED between the human and
rodent proteins (construct schematic in Figure S5).
All of these 12 chimeric CD317 proteins could be expressed in
293T cells, and the migration pattern of the chimeric proteins in
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Figure 3. CD317 Inhibits HIV-1 Particle Release in a Concentration-Dependent Manner, and Vpu Counteracts the Activity of the Human
Restriction Factor, but Not of the Rodent Orthologs
(A and B) Titration of plasmids encoding untagged human, mouse, or rat CD317 or no protein (vector) in 293T cells cotransfected with either pHIV-1 WT or
pHIV-1Dvpu and analyzed for the yield of virion-associated HIV-1 p24CA (A) and for effect on the percentage of HIV-1 release (B) as described in the legend
to Figure 1. In (B), values obtained for vector-transfected controls were set to 100%. Values are arithmetic means ± SD from one representative experiment
out of two.
(C and D) 293T cells were transfectedwith pHIV-1Dvpu (1.2 mg, open bars), expression plasmids encoding HA-CD317 or HA alone (vector) (all 60 ng), and different
concentrations of pcDNA-Vphu (0, 3, 13, 40, and 120 ng). The amount of proviral DNA as well as the total amount of DNA per transfection was kept constant. A
transfection with pHIV-1 WT was included as reference (filled bar). The yield of infectious HIV-1 virions was quantified in a standardized TZM-bl reporter assay,
and the vector-cotransfected HIV-1Dvpu control was set to 100% (C). Histograms depict arithmetic means ± SD of triplicates. Western blot analyses of corre-
sponding 293T cell lysates for Vpu or Gag proteins are shown (D). Values are arithmetic means ± SD from one representative experiment out of two.
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Figure 4. Critical Determinants for Vpu Counteraction Are Dispersed Across All Three Major Domains of CD317
(A–F) Effect of transient expression of wild-type, CT chimeric (A), TM chimeric (C), or ED chimeric (E) HA-CD317 proteins on infectious titers of Vpu-defective HIV-1
released by 293T cells cotransfected with pHIV-1Dvpu (1.2 mg), expression plasmids encoding HA-CD317 or HA alone (vector), and either pcDNA-Vphu (120 ng)
or an empty vector. The insets in (A), (C), and (E) depict the predicted topology of CD317 with the modified domain highlighted in red. Histogram bars give arith-
metic means ± SD of triplicates. Also shown are western blot analyses for Vpu, HA-CD317, or MAPK in corresponding 293T cell lysates (B, D, and F).
(G) Protein levels of HA-CD317 proteins andMAPKwere quantified byOdyssey Infrared Imaging System andOdyssey software. The ratio of values for HA-CD317
and MAPK for vector-cotransfected cells was set to 100%. Histogram bars depict the arithmetic means ± SEM of three independent experiments. ***p < 0.001
(Student’s t test).
(H) Microscopic images of 293T cells cotransfected with expression plasmids for Vpu-HcRed and either human (top) or rat (bottom) HA-CD317 proteins. Cells
were fixed and stained with anti-HA mAb HA.11, followed by Alexa 488-conjugated secondary antibodies (green). Yellow color in merged, low magnification
images reflects cellular coexpression of Vpu-HcRed (red) and HA-CD317 (green). Scale bar: 10 mm.SDS-PAGE analyses was complex (Figures 4B, 4D, 4F, and S6),
which was primarily due to differential N-glycosylation (Fig-
ure S1). The subcellular distribution pattern of the human and
rodent orthologs, as with many of the HA-CD317 chimeras,
varied between numerous small vesicular structures and fewer
larger accumulations (Figures S9 and S10). Upon coexpression
with HIV-1Dvpu, all CT, TM, and ED chimeras, as with the three
wild-type HA-CD317 proteins, induced a redistribution of Gag
into aggregates at the plasma membrane and/or intracellularly
(Figure S10). Importantly, all 12 CT, TM, or ED chimeric HA-
CD317 proteins potently inhibited the release of Vpu-defective
HIV-1 at high expression levels of the restriction factor290 Cell Host & Microbe 5, 285–297, March 19, 2009 ª2009 Elsevier(Figure S6). The amount of plasmid required to achieve 50%
inhibition of HIV-1 titers did not differ by more than 4-fold among
the three wild-type CD317 proteins and most of the chimeric
CD317 proteins, with the exception of four of these (Figure S7).
To determine susceptibility of the CD317 chimeras to Vpu
antagonism, an experimental setup identical to that used to
generate the data shown in Figures 3C and 3D was used. The
amounts of cotransfected HA-CD317 plasmids were adjusted
for each individual chimera to achieve a comparable degree of
release restriction in the absence of Vpu. Remarkably, the
inhibitory effect on release of HIV-1Dvpu induced by all HA-
CD317(CT) chimeras (Figures 4A and 4B), HA-CD317(TM)Inc.
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(Figures 4E and 4F) could not be counteracted by Vpu. This is
consistent with the nearly superimposable titration curves for
the restriction factors for wild-type and Vpu-defective HIV-1
(Figure S7). Specifically, transfer of the CT, TM, or ED from the
rodent orthologs to HA-hCD317 resulted in resistance to the viral
antagonist. Conversely, HA-rodent CD317 chimeras carrying the
CT, TM, or ED from the human protein remained resistant to Vpu
counteraction (Figures 4A, 4C, 4E, and S7). Collectively, this
highlights a complex and apparently interdependent set of deter-
minants located in the three domains of the human restriction
factor that underlie its susceptibility to antagonism by the HIV-1
Vpu protein. Notably, of the 15 wild-type and human/rodent
chimeric CD317 proteins analyzed, all displayed anti-HIV-1
activity, albeit with variable potency for some of the chimeras,
but only the human protein could be antagonized by the action
of Vpu. Thus, retroviral restriction appears to be a general and
evolutionarily conserved feature of CD317, while antagonism
by the Vpu protein of HIV-1 is specific for the human or possibly
also other primate CD317 proteins.
Successful Antagonism by Vpu Correlates
with the Depletion of Cellular Pools of HA-CD317
We noted that cellular levels of hCD317, but not of the rodent or
chimeric CD317 proteins, were markedly reduced when Vpu
was coexpressed (Figures 4B, 4D, and 4F). Quantitative western
blot analyses with concurrent virological evaluation showed that
the presence of Vpu resulted in a depletion of steady-state levels
of HA-hCD317 by 93% relative to vector controls (Figure 4G). In
contrast, expression of Vpu had no significant effect on mouse
or rat CD317 protein levels (Figure 4G). This phenotype was
corroborated by microscopic analysis of cells expressing Vpu-
HcRed and HA-CD317. Expression of rodent CD317 protein (rat
or mouse) was readily detectable in over 90% of Vpu-HcRed-
positive 293T cells,whereas expression of hCD317was detected
in less than 20% of such cells (Figure 4H [low magnification
image] and data not shown). Furthermore, a Vpu-dependent
depletion of cellular pools of HA-CD317 was also seen in HA-
hCD317-expressing 293T cells following infection with VSV-G
pseudotyped HIV-1 (Figure S8). Therefore, the species-specific
capacity of Vpu to functionally antagonize the CD317-mediated
release restriction correlated with Vpu’s ability to deplete cellular
pools of the ectopically expressed restriction factor.
HIV-1 Depletes Endogenous hCD317 in Infected
T Cells in a Vpu-Dependent Manner
Ectopic expression of HA-tagged CD317 in 293T cells may not
faithfully recapitulate events occurring with the endogenous
restriction factor. We therefore examined levels of native
hCD317 in HIV-infected target cells, which constitutively express
substantial levels of the intrinsic immunity factor, relative to the
Vpu status and resulting virion release.
Productive infection was assessed by flow cytometry
following intracellular p24CA staining. Infection of adherent
TZM-bl cells (Figures 5A and 5B) and A3.01 T cells (Figures 5C
and 5D)with HIV-1WT induced a loss of hCD317 surface expres-
sion by 57% and 77%, respectively, relative to cells infected with
HIV-1Dvpu. This remarkable depletion of surface levels of CD317
by the WT virus coincided with a drastically enhanced release ofCell Hinfectious HIV-1 into the supernatant compared to the isogenic
Vpu-defective counterpart, while the percentage of p24CA-posi-
tive cells in these cultures differed by only 1.5-fold (TZM-bl;
Figure 5B) or 2-fold (A3.01; Figure 5D) at this early time point
postinfection.
We further performed confocal immunofluoresence micros-
copy of the above HIV-1-infected A3.01 cultures to assess total
cellular levels and distribution of hCD317 and Gag. Fifty-five
percent of A3.01 T cells infected with HIV-1Dvpu showed a
strong accumulation of HIV-1 Gag (anti-p24CA staining) at the
cell surface, consistent with virion tethering reported previously
in this cell line (Klimkait et al., 1990) and, importantly, expressed
CD317 at levels comparable to adjacent, uninfected cells (Fig-
ure 5F; 66% of Gag-positive cells coexpress CD317). Contrary
to the results obtained with HA-hCD317 overexpressed in
293T cells, the endogenous protein localized, in addition to intra-
cellular membranes, also to the plasma membrane and could
frequently be detected at sites of p24CA accumulations. In
contrast, HIV-1 WT-infected A3.01 T cells displayed a more
dispersed cytoplasmic Gag distribution with little tethering (7%
of all infected cells) and a significantly reduced frequency of
CD317 expression (Figure 5E; 25%Gag-positive cells coexpress
low levels of CD317). These results demonstrate that Vpu
expressed in HIV-1NL4-3-infected human T cells depletes the
intrinsic immunity factor CD317 to overcome the naturally
imposed cellular restriction to virion release.
Vpu Shortens the Half-Life of hCD317
To assess by which mechanism Vpu depletes cellular hCD317
species, [35S]methionine pulse-chase radiolabeling studies
were performed in 293T cells expressing HA-hCD317 together
with Vpu or a control vector. In the absence of Vpu, the radiola-
beled hCD317 protein showed a biphasic decay pattern:
following a relatively quick disappearance of 50% of the radio-
labeled protein within 1 hr of chase, the remaining protein
displayed a markedly higher stability (Figure 6A). In contrast, in
the presence of Vpu, the radiolabeled hCD317 disappeared
more rapidly, with a loss of 85% within 1 hr and a complete
disappearance by3hr of chase (Figure 6A). Notably, these exper-
imentswereconducted in the absenceof other viral components,
demonstrating that Vpu alone is sufficient to trigger the degrada-
tion of hCD317. Thus, Vpu achieves depletion of hCD317 by
accelerating its degradation and hence shortening the half-life
of the restriction factor.
Proteasome Inhibitors or the VpuS52AS56A Mutant Block
the Vpu-Mediated Depletion of hCD317, Resulting
in a Restored Restriction of HIV-1 Release
We hypothesized that the proteasome might mediate the Vpu-
induced degradation of hCD317. To test this, 293T cells were co-
transfected with pHIV-1Dvpu and pHA-hCD317 in the presence
or absence of an expression plasmid encoding Vpu. Twenty-four
hours after transfection, the medium was exchanged to remove
virions produced up to this point and, subsequently, cells were
treated for 18 hr with the proteasome inhibitors ALLN or
clasto-lactacystin b-lactone or with DMSO alone. Notably,
clasto-lactacystin b-lactone is a specific inhibitor of the 20S pro-
teasome (Fenteany et al., 1995). At the end of the experiment,
virions were purified through a sucrose cushion and quantifiedost & Microbe 5, 285–297, March 19, 2009 ª2009 Elsevier Inc. 291
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Figure 5. Expression of Endogenous hCD317 Is Lost from Cells Infected with HIV-1 WT, but Not from Cells Infected with HIV-1Dvpu
(A–D) Human TZM-bl cells (A) or A3.01 T cells (T-lymphocytic cell line) (C) were infected with VSV-G-pseudotyped HIV-1 WT or HIV-1Dvpu virus and 3–4 days
postinfection analyzed by flow cytometry using side scattering of light (FSC/SSC) to identify live cells (gate R1), surface staining to quantify endogenous hCD317
expression levels, and concurrent intracellular p24CA staining to identify productively infected cells. At the time of cell harvest for flow cytometry, supernatant was
removed to determine the yield of infectious HIV-1 (B and D). Efavirenz-treated cultures (1 mM) served as controls. Values represent arithmetic means ±
SD of triplicates and originate from one of two similar experiments.
(E and F) Single channel andmerged confocalmicrographs for the localization of HIV-1Gag (green, anti-p24CA) and endogenous hCD317 (red, anti-HM1.24/BST-
2) in A3.01 T cells fixed in parallel to the analysis in (C). Scale bar: 10 mm.by p24CA ELISA, and whole-cell lysates were subjected to
western blot analysis. Treatment with both proteasome inhibitors
completely abrogated the beneficial effect of Vpu on the release
of HIV-1 particles (Figure 6B). Consistent with the idea that HIV-1
release inhibition is mediated by cellular levels of the restriction
factor, HA-hCD317 steady-state levels were drastically elevated
in cells treated with ALLN or clasto-lactacystin b-lactone when
compared to DMSO-treated control cells, 9.3- and 9.2-fold,
respectively (Figure 6C). Notably, in the absence of Vpu, both
proteasome inhibitors reduced the production of HIV-1 2-fold
(Figure 6B), consistent with a previous report (Schubert et al.,
2000), and we observed a modest, 2-fold increase in
HA-hCD317 levels (Figure 6C).
The Vpu2/6 mutant, which carries alanine substitutions of
serine residues 52 and 56 within the cytoplasmic tail of the viral
protein, has been reported to be impaired both in its ability to
downregulate hCD317 from the cell surface (Van Damme et al.,
2008) and to promote HIV-1 release in naturally restricted HeLa292 Cell Host & Microbe 5, 285–297, March 19, 2009 ª2009 Elseviecells (Schubert et al., 1994; Van Damme et al., 2008). To directly
probe the effect of this Vpu mutant on hCD317-mediated HIV-1
restriction and cell-associated hCD317 levels, wild-type Vpu or
Vpu2/6 protein were coexpressed in 293T cells together with
HIV-1Dvpu and HA-hCD317. While Vpu expression readily over-
came the release restriction and markedly depleted HA-hCD317
levels, the Vpu2/6 mutant failed to augment the release of
Vpu-defective HIV-1 and also did not significantly impair HA-
hCD317 expression (Figures 6D and 6E). Taken together, these
results show that amino acid residues S52/S56 of Vpu and pro-
teasome activity are critical for hCD317 antagonism by the viral
protein, and that Vpu accelerates the physiological turnover of
the intrinsic immunity factor by the proteasome.
The Ability of Vpu to Augment Virion Release
and to Degrade hCD317 Strongly Correlate
Finally, we performed a Vpu dose-titration study to carefully
assess the impact of the accessory protein’s expression onr Inc.
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Figure 6. Vpu Depletes CD317 of Human Origin by Shortening Its Half-Life, Which Involves an Accelerated Degradation by the 20S
Proteasome
(A) Pulse-chase radiolabeling. 293T cells transiently cotransfected with pHA-hCD317 together with an empty vector or pcDNA-Vphu were pulse-labeled and then
incubated with chase media for the indicated time points. After immunoprecipitation with anti-HA antibody, proteins were separated by SDS-PAGE, and the gels
were subjected to autoradiography (left panel). The relative intensity of the HA-hCD317 bands was quantified, and values at 0 hr were set to 100 and graphed.
Given are the arithmetic means ± SD of three independent experiments (right panel).
(B and C) Proteasome inhibitor study. 293T cells were cotransfected with pHIV-1Dvpu together with pcDNA-Vphu or an empty control vector. Twenty-four hours
after transfection, the medium was exchanged to remove virions produced up to this point. Cells were then cultivated for 2 hr in the presence of the proteasome
inhibitors ALLN (25 mM) or clasto-lactacystin b-lactone (20 mM) orwith DMSOalone (0.25%), washed again, and then treated for an additional 16 hr in the presence
of drugs until harvest. Shown are virion-associated p24CA levels in supernatants (B) and western blot analyses of corresponding 293T cell lysates for Vpu,
HA-hCD317, and MAPK with quantified ratios for HA-hCD317/MAPK signals given below (DMSO-treated vector controls set to 1.0) (C). Values represent
arithmetic means ± SD of triplicates and originate from one representative experiment out of two.
(D and E) Vpu mutant study. 293T cells were transfected to express HIV-1Dvpu and HA-hCD317 together with either wild-type Vpu (‘‘Vpu’’) or a mutant, in which
S52 and S56 are replaced by alanine (‘‘Vpu2/6’’). Two days posttransfection, the yield of infectious HIV-1 (D) and levels of Vpu, HA-hCD317, and MAPK (E) were
analyzed. The percentage of HA-hCD317/MAPK expression relative to Vpu-negative control cells, set to 1.0, is given. Values represent arithmetic means ± SD of
triplicates and originate from one of two similar experiments.HIV-1 release in relation to its ability to deplete levels of hCD317
in virus-producing cells. To this end, 293T cells were cotrans-
fected with a constant, intermediate amount of pHA-hCD317
and pHIV-1Dvpu together with decreasing amounts of the
expression plasmid encoding Vpu. In addition, a cotransfection
with pHIV-1 WT was included. Culture supernatants and whole-
cell lysates were analyzed 48 hr later.
Coexpression of HA-hCD317 with HIV-1WT (but not with Vpu-
defective HIV-1) allowed, as expected, high-level release of
infectious virions (Figure 7A). Thiswas accompanied by amarked
depletion of HA-hCD317 in 293T producer cells (Figure 7B). For
Vpu-defective HIV-1, virion release was rescued by coexpres-
sion of Vpu in a concentration-dependent manner, and also
a concentration-dependent depletion of cellular HA-hCD317
was observed (Figures 7A and 7B). Importantly, a more refined
correlative and quantitative analysis of these twoVpu-modulatedCell Hparameters revealed that depletion of the restriction factor (Fig-
ure 7C, filled circles) and values for release of infectious HIV-1
(Figure 7C, open triangles) closely matched across the entire
range of coexpressed Vpu concentrations. Moreover, replotting
of values for these two parameters, i.e., infectious HIV-1 release
and HA-hCD317 depletion, from Figure 7C demonstrated
a strong positive correlation (Figure 7D, open squares) (Pear-
son’s correlation coefficient: r = 0.94; p = 0.0005). Of note, plot-
ting of values for these two parameters obtained for HIV-1 WT
(Figures 7A and 7B) fit well into this quantitative relationship
established for Vpu-defective HIV-1 in the context of trans-com-
plemented Vpu (Figure 7D, filled square). Collectively, these
findings provide strong evidence for an important mechanistic
role of CD317 degradation by Vpu from HIV-1NL4-3 for the acces-
sory protein’s ability to overcome the restriction of the intrinsic
immune factor in human cells.ost & Microbe 5, 285–297, March 19, 2009 ª2009 Elsevier Inc. 293
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Retroviruses display species-specific patterns of infection and
pathogenesis. The impairment of retroviral replication in foreign
and sometimes even in cognate hosts stems, in part, from the
action of host-encoded restriction factors. These cellular factors
can interfere with distinct steps of the replication cycle of diverse
viral pathogens and are thus an important arm of the innate
defense system. Many retroviruses have, in turn, evolved gene
products that can inactivate or overcome these intrinsic antiviral
barriers by diverse strategies that at present are frequently still
poorly understood. Here, we report that HIV-1 has evolved its
Vpu gene product to antagonize the intrinsic immunity factor
CD317 in human but not in rodent cells. This species-specific
antagonism involves the Vpu-mediated depletion of cellular
pools of hCD317 by targeting the restriction factor for degrada-
tion by the 20S proteasome.
For Vpu-defective HIV-1, expression of CD317 from human,
mouse, or rat induced a virion release block that was character-
ized by an accumulation of mature particles tethered to the cell
surface or to each other, as well as by virion clusters in seemingly
intracellular compartments. Despite their profound sequence
A
B
C D
Figure 7. The Ability of Vpu to Deplete CD317
Closely Correlates with its Capacity to Enhance
HIV-1 Release
(A and B) 293T cells were transfected by calcium phos-
phate precipitation with three different plasmids: (1)
pHA-hCD317 (100 ng), (2) either pHIV-1 WT or pHIV-
1Dvpu (1.2 mg), (3) different amounts of pcDNA-Vphu
(0, 150, 75, 37.5, 18.8, 9.4, 4.7, or 2.3 ng). As a reference,
pHIV-1Dvpu or pHIV-1 WT were also expressed in cells in
the absence of trans-complemented Vpu and HA-
hCD317. Forty-eight hours later, supernatants and
whole-cell lysates were analyzed for HIV-1 infectivity (A)
and relative levels of HA-hCD317 and Vpu, respectively
(B), as detailed above. Values represent arithmetic
means ± SD of triplicates.
(C) Quantification and correlative analysis of infectious
HIV-1 release (A) and HA-hCD317 depletion (B) upon
Vpu titration. Open triangles: the percentage of HIV-
1Dvpu virions secreted in the presence of HA-hCD317
and different amounts of trans-complemented Vpu are
given relative to HIV-1Dvpu levels secreted in the absence
of Vpu and HA-hCD317, which was set to 100% (data
taken from [A]). Filled circles: the percentage of HA-
hCD317 depletion is given with relative levels for lysates
of HIV-1Dvpu- and HA-hCD317-transfected cells in the
absence of Vpu set to 0%depletion (data derived from [B]).
(D) Relative levels of HA-hCD317 depletion and released
HIV-1 for different Vpu concentrations from (C) plotted
against each other (open squares). For these values, the
Pearson’s correlation coefficient r and the corresponding
p value were calculated using GraphPad Software (indi-
cated in [D]). The filled square depicts the value obtained
for HIV-1 WT in (A) and (B).
heterogeneity, human and rodent CD317 ortho-
logs therefore exert comparable anti-HIV-1
activities by targeting the virion release step,
presumably by a common mechanism. The
antiretroviral activity of CD317 thus appears to
be evolutionarily conserved, regardless of whether the viral
pathogen naturally infects the species.
The molecular mechanism by which CD317 inhibits release of
retroviral particles from productively infected cells is still unclear.
Based on its highly unusual predicted topology, ability to form
dimers via disulfide bonds, and colocalization of HA-hCD317
and Gag.GFP in 293T cells, CD317 has been suggested to
bridge cell-virion or virion-virion interactions by placing one of
its two lipid-anchoring domains in each membrane or by dimer-
ization of two juxtaposed CD317 molecules (Neil et al., 2008).
Our analyses of 293T cells presented herein, however, did not
provide evidence for a physical involvement of CD317. Confocal
and immunoelectron microscopy failed to identify substantial
colocalization between HIV-1 Gag and ectopically expressed
HA-CD317, while antiviral activity of the restriction factor was
readily exerted. CD317, detected through an intracytoplasmic
N-terminal HA-epitope tag, predominantly localized to intracel-
lular membranes and not to the cell surface, from which virions
bud, and no enriched labeling was detected on virions and
budding sites. On the contrary, endogenous hCD317 in human
A30.1 T cells, detected through an epitope in the ED (Ishikawa
et al., 1995), was found more prominently at the plasma
294 Cell Host & Microbe 5, 285–297, March 19, 2009 ª2009 Elsevier Inc.
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infected cells. These puzzling results warrant future studies into
the mechanism by which CD317 affects HIV-1 particle release in
different cell types.
Independent of the subcellular localization of CD317 action, it
seems counterintuitive that the apparent virion release defect
with accumulations of tethered virions at the plasma membrane
does not lead to increased levels of cell-associated p24CA, as
also noted in two recent studies (Neil et al., 2008; Van Damme
et al., 2008). However, it is unclear what fraction of the total
amount of cell-associated p24CA is truly reflected by these
morphologically striking virion aggregates and, in addition, Bien-
iasz and colleagues have reported an enhanced endocytosis
rate of tethered virions and accumulation in endosomes prior
to targeting for degradation (Neil et al., 2006). Together, this
may contribute to a balance between the enhancement (teth-
ering) and reduction (degradation) of cell-associated p24CA
levels in CD317-expressing cells, and future mechanistic studies
should address this in more detail.
In contrast to the conserved anti-HIV-1 activities of human and
rodent CD317 proteins, viral antagonism of these orthologs was
species-specific. A comprehensive set of interspecies CD317
chimeras revealed that the rodent-specific resistance as well
as the human-specific susceptibility to Vpu antagonism have
a complex genetic basis and are governed by determinants in
the CT, TM, and ED of the intrinsic immunity factor. Furthermore,
the species-specific functional antagonism of Vpu correlated
with the ability of Vpu tomodulate cellular pools of the respective
restriction factor. This is in contrast to an experiment presented
by Neil and colleagues (Neil et al., 2008), which did not show
altered HA-hCD317 levels upon Vpu coexpression. In our study,
the reduction of steady-state levels of hCD317 by Vpu was
demonstrated by quantitative western blot analyses, in line with
initial observations by Bartee and colleagues (Bartee et al.,
2006). In addition, confocal microscopy revealed a profound
reduction in the number of cells expressing HA-hCD317 upon
coexpression of Vpu-HcRed or upon infection with HIV-1 WT,
but not HIV-1Dvpu. Furthermore, productive HIV-1NL4-3 infection
of human A3.01 T cells led to marked reduction of cell surface
levels and intracellular pools of endogenous CD317. In contrast,
levels of rodent CD317 proteins were unaltered by coexpression
of Vpu. Mouse and rat CD317 are thus resistant to Vpu counter-
action and act as potent inhibitors of wild-type HIV-1 infection.
We propose that proteasomal degradation of CD317 lies at the
heart of the action of Vpu from HIV-1NL4-3 and is the key mech-
anism by which the wild-type virus overcomes the restriction of
virion release in infected human T cells. In support of this notion,
this manuscript presents the following findings: first, Vpu heavily
impairs the intracellular stability of hCD317. Second, efficacies
of HIV-1 release rescue and depletion of hCD317 in Vpu titration
studies were strictly correlated. Also of interest in this context,
overexpression of hCD317 potently inhibited the release of
Vpu-expressing HIV-1 WT, demonstrating that the viral antago-
nism of the ‘‘Vpu-sensitive’’ human restriction factor is saturable.
Third, the Vpu-induced degradation of hCD317 involves the
proteasome, since addition of proteasomal inhibitors completely
blocked the ability of Vpu to deplete CD317 and effectively elim-
inated the Vpu-induced rescue of virion release. Fourth, the
Vpu2/6 mutant, which fails to promote HIV-1 release in restrictedCell HHeLa cells (Schubert et al., 1994; Van Damme et al., 2008),
neither depleted hCD317 nor overcame the virion release restric-
tion. Thismapping provides an initial insight into possible similar-
ities between the pathways by which Vpu targets the viral entry
receptor CD4 and the innate immunity factor CD317 for protea-
somal degradation, i.e., via pathways involving b-TrCP and E3
ubiquitin ligases (Malim and Emerman, 2008). Fifth, Vpu ex-
pressed in HIV-1NL4-3-infected human T cells depleted hCD317
and overcame the naturally imposed cellular restriction to virion
release. Finally, the rodent orthologs were resistant to both Vpu-
mediated degradation and release rescue. Collectively, these
findings provide strong evidence for the mechanistic importance
of Vpu-mediated CD317 degradation for the accessory protein’s
ability to overcome the restriction imposed by the intrinsic
immunity factor. At this point, additional, degradation-indepen-
dent effects of Vpu on virion release in the context of CD317
expression, as well as Vpu allele-specific effects, cannot be
excluded.
Adding another level of complexity to the restriction of retro-
viral release by the intrinsic immune system, human calcium-
modulating cyclophilin ligand (CAML) was recently identified by
Varthakavi et al. as a second Vpu-sensitive host restriction factor
that inhibits the release of HIV from human cells (Varthakavi et al.,
2008). Thus, humans express at least two structurally unrelated
cellular proteins that either coordinate or directly mediate restric-
tion at the final step in the retroviral replication cycle. The
combined action of hCD317 and hCAML may conceivably
account for the long-known dominant cellular restriction pheno-
type to HIV release.
Species-specific cellular factors like CD317 impose barriers to
retroviral infection. The fact that Vpu fromHIV-1 can successfully
interfere with the intrinsic antiviral action of CD317 in humans,
but not in rodents, hints at the evolutionary importance of this
ability. This species-specific activity may not only oppose
zoonotic transmission—reflected, in part, also by difficulties in
establishing high-viremic rodent models of HIV disease—but
provides an important resource for understanding fundamental
principles of virus-host interaction. Insight from the current study
into HIV-1 Vpu and previous work on HIV-1 Vif, which also
depletes intracellular pools of its cellular counterplayer
APOBEC3G in a species-specific fashion (Browne and Littman,
2008; Goila-Gaur and Strebel, 2008; Mariani et al., 2003; Stopak
et al., 2003), highlight that the struggle over expression levels of
intrinsic immunity factors is a general theme of virus-host coevo-
lution. The antiviral potency combined with the Vpu resistance of
rodent CD317 identified herein will guide in vivo strategies for the
advancement of transgenic small animal models of HIV infection
(Keppler et al., 2002). Furthermore, the Vpu-CD317/CAML axis in
the context of species-specific interaction patterns forms a
potential target for the development of novel anti-HIV drugs.
EXPERIMENTAL PROCEDURES
Plasmids
pCMV-SPORT6-hBST2/hCD317 and pCMV-Sport6-mBST2/mCD317 were
from Open Biosystems (Huntsville, AL). pCMV-SPORT6-rCD317 was gener-
ated by subcloning of rBST2 cDNA (Kupzig et al., 2003) into pCMV.SPORT6
with EcoRI. pcDNA3.1/neo-based expression vectors for CD317 from all three
species containing amino-terminal HA-epitope tags were generated by PCR.
Human-rodent HA-CD317 CT, TM, or ED domain chimeras were designedost & Microbe 5, 285–297, March 19, 2009 ª2009 Elsevier Inc. 295
Cell Host & Microbe
Species-Specific CD317 Subversion by HIV-1with CloneManager based on topological predictions (Kupzig et al., 2003) (see
also Figures 1A, 4A, 4C, 4E, S6, and S7), and corresponding oligonucleotide
fragments were synthesized by Geneart. Fragments containing rodent CT,
TM, or ED domains in the context of hCD317 were subcloned into
pcDNA3.1-HA-hCD317 with KpnI and BbvCI. Fragments containing the CT,
TM, or ED domain of human origin in the context of pcDNA3.1-HA-mCD317
were subcloned with KpnI and BsmBI. The subcloning of the CT, TM, or ED
domains from humans in the context of pcDNA3.1-HA-rCD317 was carried
out with KpnI and PpuMI or SgrAI and PpuMI, respectively. The subviral
plasmid psyngagpol, encoding codon-optimized gag and pol from HIV-1NL4-3,
was from Ralf Wagner (University of Regensburg, Germany). The plasmid
pcDNA-Vphu, expressing a codon-optimized, Rev-independent HIV-1NL4-3
Vpu protein (Nguyen et al., 2004), was from Klaus Strebel (National Institutes
of Health; Bethesda, MD), and pVpu-HcRed encoding this codon-optimized
Vpu fused to HcRed was from Paul Spearman (Emory University School of
Medicine; Atlanta) (Varthakavi et al., 2006). The Vpu S52AS56A mutant
(‘‘Vpu 2/6’’) was generated by site-directed mutagenesis from pcDNA-Vphu.
Viruses
Proviral plasmids pHIV-1NL4-3WT (BH10Env) and pHIV-1NL4-3Dvpu (BH10Env)
(Pfeiffer et al., 2006)were fromValerie Bosch (DeutschesKrebsforschungszen-
trum; Heidelberg, Germany). Supernatants from provirus-transfected cells
were harvested on day 2 posttransfection, and virions pelleted through
a 20% sucrose cushion by ultracentrifugation (44,000 g, 4C, 60 min) and re-
suspended in PBS (infectivity analysis) or 1% Triton X-100/PBS (immunoblot-
tingorp24CAELISA).Pellets of transfectedcellswerewashed inPBSand lysed
in SDS-lysis buffer for immunoblot or 1% Triton X-100/PBS for p24CA ELISA.
The virion- and cell-associated amount of HIV-1 p24CA antigen was deter-
mined by an antigen enzyme-linked immunosorbent assay (p24CA ELISA)
(Keppler et al., 2005). Of note, this ELISA is at least 1000-fold less sensitive
for the detection of Pr55Gag compared to p24CA (H.-G.K., unpublished data).
Cells and Transfections
All cell lines were obtained from the American Type Culture Collection and
cultivated under standard condition in Dulbecco’s modified Eagle’s medium
or RPMI1640 supplemented with 10% fetal bovine serum, 1% penicillin-strep-
tomycin, and 1% L-glutamine (all from Invitrogen; Carlsbad, CA). 293T cells
were transfected by calcium phosphate DNA precipitation or FuGENE 6
(Roche Diagnostics; Risch, Switzerland).
HIV-1 Infectivity Assay
The infectivity of HIV-1 was determined 48 hr after infection in a standardized
96-well titration assay on TZM-bl cells by luminometric analysis of firefly
luciferase activity (Geuenich et al., 2008).
Confocal Immunofluorescence Microscopy
Transfected cells growing on coverslips were fixed with 4%paraformaldehyde
and permeabilized for 2min with 0.1%Triton X-100 in PBS. Cells were blocked
for 1 hr with 1% bovine serum albumin in PBS and stained for p24CA and HA
using appropriate primary and secondary antibodies as described (Fackler
et al., 2006; Hannemann et al., 2008). Coverslips were mounted in mounting
medium (Dianova; Hamburg, Germany) and analyzed with a Zeiss LSM 510
confocal microscope with a 1003 PLAN-APO objective lens. Images were
recordedwith the Zeiss proprietary software LSM5 and processedwith Adobe
Photoshop 6.0. Gag localization was classified for individual cells in principle
as reported (Neil et al., 2008).
Proteasome Inhibitors
ALLN and clasto-lactacystin b-lactone were purchased from Calbiochem
(San Diego, CA) and used as detailed in the legend to Figure 6.
Immunoblotting
Cells were lysed in either buffer A (50mMHEPES, 135mMNaCl, 10%glycerol,
1% Triton X-100, 1 mM EDTA) or protease inhibitor cocktail (Sigma; St. Louis),
pH 7.2, for 1 hr at 4C. Lysates were collected after centrifugation at 13,2003 g
for 20 min at 4C and analyzed for protein concentration using the BCA protein
assay (Pierce; Rockford, IL). Alternatively, cell pellets were directly resus-
pended in SDS-lysis buffer. Proteins were run on a 10% or 12.5% SDS-296 Cell Host & Microbe 5, 285–297, March 19, 2009 ª2009 ElseviePAGE and transferred onto nitrocellulose. Blocked membranes were probed
with the following primary antisera/antibodies: rabbit polyclonal serum anti-
HIV-1 p24CA, anti-Vpu (from Eric Cohen, Institut de recherches cliniques de
Montre´al), anti-MAPK (Santa Cruz Biotechnology; Santa Cruz, CA), as well
asmouse anti-HAmAbHA.11 (Covance; Princeton, NJ). Secondary antibodies
were conjugated to either horseradish peroxidase for ECL-based detection or
Alexa 700/800 fluorescent dyes for detection by Odyssey Infrared Imaging
System (LI-COR Biosciences; Lincoln, NE) and quantification by Odyssey
software (version 2.1).
Supplemental Data report details on electron microscopy, HIV-1 Gag and
hCD317 pulse-chase analysis, flow cytometric analysis of infected cells, and
immunoprecipitation and deglycosylation of HA-CD317 chimeras.
SUPPLEMENTAL DATA
Supplemental Data include Supplemental Experimental Procedures, Supple-
mental References, and ten figures and can be found online at http://www.
cell.com/cellhostandmicrobe/supplemental/S1931-3128(09)00062-6.
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